Drug Profile
Research programme: pegylated cancer therapeutics - Polaris Pharmaceuticals
Alternative Names: Histidase-PEG 20; PEG-histidase; PEG-TNF - Phoenix Pharmacologics; PEG-TNFα; PEGylated TNF - Phoenix Pharmacologics; TNF-PEG 20Latest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator Phoenix Pharmacologics
- Developer Polaris Pharmaceuticals
- Class Blood proteins; Enzymes; Glycoproteins; Monokines; Polyethylene glycols; Tumour necrosis factors
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Cancer (Combination therapy) in USA (Parenteral)
- 22 Feb 2023 Discontinued - Preclinical for Cancer in USA (Parenteral)
- 28 Sep 2018 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)